Catalyst Wire Dossier Catalyst Wire Dossier

N-Rephasin SAL200

N-Rephasin SAL200 · Intron Biotechnology, Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for N-Rephasin SAL200, covering 2021-08-17 to 2021-11-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers [Phase 1]

See pricing